DBV Technologies reported $189.6M in Current Assets for its fiscal quarter ending in September of 2026.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.27B 43.88M Sep/2026
Alnylam Pharmaceuticals USD 5.11B 492.49M Sep/2026
Amarin USD 612.88M 10.12M Sep/2026
BioCryst Pharmaceuticals USD 531.15M 46.47M Sep/2026
BioMarin Pharmaceutical USD 3.92B 50.99M Sep/2026
DBV Technologies USD 189.6M 12.3M Sep/2026
Galectin Therapeutics USD 27.29M 1.83M Jun/2024
Halozyme Therapeutics USD 1.85B 913.71M Sep/2026
Incyte USD 5.52B 505.2M Sep/2026
Insmed USD 1.71B 72.59M Sep/2026
Ionis Pharmaceuticals USD 2.36B 129.77M Sep/2026
Neurocrine Biosciences USD 2.01B 370.7M Sep/2026
PTC Therapeutics USD 2.54B 79.58M Sep/2026
Sarepta Therapeutics USD 2.27B 49.06M Sep/2026
Ultragenyx Pharmaceutical USD 544M 62M Sep/2026
United Therapeutics USD 2.88B 603.5M Sep/2026